Hemolysis is a common complication of plasmapheresis using membrane filtration but is infrequent in the procedures using the centrifugation method. 1 Double-filtration plasmapheresis (DFP) consists of a first filter, which separates plasma from blood (a plasma separator), and a second filter, which separates albumin from larger molecules in the plasma (a plasma fractionator), including immunoglobulins, immune complexes, and lipoproteins. 2 Hemolysis is by far the most common complication of DFP and occurs in approximately 20% of the procedures. 3, 4 Although previous studies have shown that there are usually no clinical consequences or symptoms related to hemolysis, 3-5 hemolysis per se often interferes with the operation and causes early termination of these procedures. Hemolysis during DFP is attributed to increased transmembrane pressure (TMP), which causes alteration in the plasma flow, shearing forces, and sieving, leading to hemolysis. 6 To evaluate the occurrence of hemolysis during DFP treatment and its causes, we prospectively treated 113 patients with severe myasthenia gravis (MG) using a standard DFP protocol and monitored plasmapheresis-related parameters, including TMP, pressure measured at the arterial blood line (Pa), and pressure measured at the venous blood line (Pv) at 30-minute intervals during treatment. Clinical and laboratory parameters related to the development of hemolysis were also analyzed.
To evaluate the occurrence of hemolysis during double-filtration plasmapheresis (DFP) treatment and its causes, we prospectively treated 113 myasthenic patients and monitored transmembrane pressure (TMP), arterial line pressure (Pa), and venous line pressure (Pv) at 30-minute intervals (M30, M60, M90, and M120) during treatment. Laboratory and clinical parameters related to the development of hemolysis were also analyzed. The overall frequency of hemolysis was 35.4%. Peripheral venous access was associated with a higher rate of hemolysis (45.3%). The mean TMP increased significantly after M30 for the hemolysis group compared with the no hemolysis group. A similar trend was present for Pa. Pv did not differ between the 2 groups during treatments until M90 and M120. Pa and TMP changed significantly with time (both P < .0001). Vascular access through large veins and stable TMP during the procedure may help avoid hemolysis.
Hemolysis is a common complication of plasmapheresis using membrane filtration but is infrequent in the procedures using the centrifugation method. 1 Double-filtration plasmapheresis (DFP) consists of a first filter, which separates plasma from blood (a plasma separator), and a second filter, which separates albumin from larger molecules in the plasma (a plasma fractionator), including immunoglobulins, immune complexes, and lipoproteins. 2 Hemolysis is by far the most common complication of DFP and occurs in approximately 20% of the procedures. 3, 4 Although previous studies have shown that there are usually no clinical consequences or symptoms related to hemolysis, [3] [4] [5] hemolysis per se often interferes with the operation and causes early termination of these procedures. Hemolysis during DFP is attributed to increased transmembrane pressure (TMP), which causes alteration in the plasma flow, shearing forces, and sieving, leading to hemolysis. 6 To evaluate the occurrence of hemolysis during DFP treatment and its causes, we prospectively treated 113 patients with severe myasthenia gravis (MG) using a standard DFP protocol and monitored plasmapheresis-related parameters, including TMP, pressure measured at the arterial blood line (Pa), and pressure measured at the venous blood line (Pv) at 30-minute intervals during treatment. Clinical and laboratory parameters related to the development of hemolysis were also analyzed. years; SD, 16.1 years) enrolled in the study. The duration of disease ranged from 1.5 to 12.9 years. All patients were affected by severe generalized or respiratory MG, with Osserman classifications of group 2 or 3. Plasmapheresis was performed for patients with disease refractory to traditional medications. All patients received anticholinesterase therapy, 103 had received immunosuppressants including corticosteroid or azathioprine. Medications in use before plasmapheresis were continued throughout the treatment period.
Apheresis
Informed consent was obtained from all patients before their inclusion in the study. An apheresis technician administered all DFP procedures in the plasmapheresis center under the supervision of plasmapheresis specialists. DFP is a dualchannel pumping system. By using the first pump (blood pump), the native blood was pumped into the first filter (a plasma separator) and separated into its plasma and cellular components. Then the second pump (plasma pump) propelled the filtrated plasma into the second filter (a plasma fractionator), which separates albumin from larger molecules in the plasma, including immunoglobulins, immune complexes, and lipoproteins. 2 DFP was performed using a Plasmacure plasma separator (Kuraray, Osaka, Japan) and an Evaflux 4A plasma fractionator (Kuraray) in a KM 8800 automated membrane plasmapheresis monitor (Kuraray).
Our standard protocol for DFP consists of isovolumetric isotonic saline replacement, after filtration of 1 estimated plasma volume, and a constant flow rate to minimize the effect of volume changes. 7 The flow rate of the plasma pump was set at 30% of the first blood pump, and the speed of the drain pump was set at 10% of the plasma pump. Each course of treatment consisted of 3 to 5 consecutive DFP sessions within 10 days. Heparin was used as the anticoagulant. Based on the manufacturer's recommendation, the loading dose of heparin was 2000 IU, and the maintenance dose was 1,000 IU per hour. Vascular access consisted of double-lumen catheters in central veins (60 patients) or dialysis catheters (FASFLO AVFistula, Enfield Med, Taipei, Taiwan) with 17-gauge needles in the antecubital vein (53 patients). The same type of catheters were used in all patients.
Laboratory Tests
Plasmapheresis-related parameters (TMP, Pa, and Pv) were monitored at 30-minute intervals (baseline, M30, M60, M90, and M120) during the procedure. The Pa and Pv were measured from entry site (for Pa) and exit site (for Pv) of the plasma separator via pressure sensors. Only parameters in the first DFP session were used for analysis to avoid the possible influence of hypoproteinemia resulting from consecutive plasmapheresis. Hemolysis was determined by inspection of the pinkish discoloration of plasma in the plasma separator by 1 trained technician. We divided our patients into hemolysis (HL) and no hemolysis (NH) groups based on the presence or absence of hemolysis. Preplasmapheresis laboratory studies included CBC counts and serum levels of albumin, globulin, IgG, IgA, IgM, triglycerides, cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Statistical Analysis
The clinical and technical parameters related to the plasmapheresis in both groups were compared using 2-tailed Student t tests. The χ 2 test for independence was used in comparison of the percentage of vascular access sites and sex. This study also compared the changes of TMP, Pa, and Pv with the presence of hemolysis because the hypothesis was that there would be differences in changes of 3 pressures among subjects with or without hemolysis after adjustment for plasmapheresis duration, type of vascular access, and heparin dose. A repeated-measures general linear model was used to compare the examined pressures for the presence of hemolysis. Because differences were expected related perhaps to plasmapheresis duration, type of vascular access, and heparin dose for hemolysis, the baseline TMP, Pa, and Pv were compared with follow-up results. A P value of .05 or less was considered statistically significant.
Results
Hemolysis was noted in 40 (35.4%) of 113 patients. ❚Table 1❚ summarizes the demographic and laboratory characteristics for the 113 patients with MG. There were no significant differences between groups in terms of age, sex, filtered plasma volume, blood pressure, blood flow, and pre-DFP laboratory data except for a higher WBC count in the HL group (P = .0197). The HL group had a higher percentage of peripheral venous punctures as the vascular access site (P = .0389) and a higher mean body weight (P = .0282). Consequently, the HL group also had a longer duration of DFP treatment (P = .0017) and a higher dose of heparin (P = .0053).
During DFP, the TMP is usually kept below 50 mm Hg. At M30, 13 patients in the HL group had TMPs above the ideal measurement of 50 mm Hg. The TMP rose gradually as filtration continued. In 38 patients, the TMPs were greater than 50 mm Hg at M60, 27 in the HL and 11 in NH groups. At M90, 71 patients had higher TMPs, 40 in the HL and 31 in NH groups. Overall, an ideal TMP was maintained throughout the entire DFP course for 41 patients in the NH group (56%) and for only 1 in the HL group (3%).
❚Figure 1❚ illustrates the mean TMP change over time, comparing the HL and NH groups at fixed intervals. The baseline TMP did not differ significantly between the HL and NH groups (21.2 vs 20.5 mm Hg). In the NH group, the mean TMP increased gradually from a mean of 20.5 mm Hg at the start of the procedure to 26.0 mm Hg at M30, and to 34.7, 44.2, and 51.4 mm Hg at M60, M90, and M120, respectively. In the HL group, the mean TMP quickly rose from a mean of 21.2 mm Hg at baseline to 53.8, 82.8, 114.8, and 131.7 mm Hg at M30, M60, M90, and M120, respectively. The mean TMP curves for the 2 groups significantly diverged after M30.
❚Figure 2❚ shows that the changes in Pa were similar to the changes in TMP between the 2 groups. The HL group had significantly higher Pa after M30. The changes in Pv during plasmapheresis were significantly different at M90 (93.1 vs 71.1 mm Hg; P = .0402) and M120 (96.4 vs 70.7 mm Hg; P = .0198) between the HL and NH groups ❚Figure 3❚.
By using a repeated-measures general linear model, a statistically significant main effect of hemolysis (P < .0001 for TMP, P < .0001 for Pa, and P = .0126 for Pv) and an interaction effect by time (P < .0001 for TMP, P < .0001 for Pa, and P = .0250 for Pv) were found. In additions, the time change of ❚Figure 1❚ Transmembrane pressure (mean and SD) monitored at 30-minute intervals during double-filtration plasmapheresis for the hemolysis and no hemolysis groups. P ≤.05 was considered statistically significant.
❚Figure 2❚ Arterial pressure (mean and SD) monitored at 30-minute intervals during the double-filtration plasmapheresis for the hemolysis and no hemolysis groups. P ≤.05 was considered statistically significant.
Pa and TMP were significant (both P < .0001). Bonferroni post hoc comparisons showed a significant difference of Pa and TMP between baseline measurements and each follow-up measurement (all P < .01).
Discussion
In this study, we used a standard protocol for DFP treatment; the hematocrit values and concentration of serum proteins and lipids were not associated with the occurrence of hemolysis based on the lack of correlation of hemolysis with the level of serum and blood components. The occurrence of hemolysis during membrane plasma separation has been related to the membrane and module properties, blood properties, and operating conditions. 8 For given membrane and module properties, the properties of blood and its concentrations of plasma solutes affect the limits of the filtration process. 9 Regarding the operating conditions during membrane plasmapheresis, Fok et al 5 reported that the vascular access through large veins, smooth blood flow, and constant plasma ultrafiltration flow were the major determinants for development of hemolysis. Our previous study on the hemodynamic effects of the different vascular access sites for DFP revealed that the central vein access group had a higher blood flow rate, a shorter duration of DFP treatment, and a lower dose of heparin. 10 In this study, vascular access through a central vein had a significantly lower percentage of hemolysis compared with access through a peripheral vein. These findings support the proposition of a contributory role for vascular access in the pathogenesis of hemolysis.
Membrane plasmapheresis is fundamentally a filtration process and, consequently, suffers from flux decline with time. 11 The rate-limiting process for blood filtration is the formation of a layer of blood cells (particle polarization) on the membrane surface. 12 The TMP is a main technical parameter governing hemolysis in membrane plasma separation. 13 Operation should be at the lowest possible TMP and generally less than 50 mm Hg. 1, 9 In our study, the TMP progressively increased throughout the entire course of plasmapheresis. In the NH group, the TMP remained below the ideal pressure of 50 mm Hg during 59% of the course. In contrast, the mean TMP jumped quickly over the ideal of 50 mm Hg at M30 in the HL group. All 13 patients with a TMP of more than 50 mm Hg at M30 eventually developed hemolysis. Therefore, the ideal TMP at M30 seems to be a good predictor for development of hemolysis during membrane filtration.
Comparison of pressure parameters recorded at fixed intervals during DFP treatment reflects the dynamic relationships among these parameters. In the present study, Pa changed similarly to TMP, especially in the early stage of DFP treatment, and was a more important determinant for TMP than Pv. Consequently, keeping a lower Pa with good vascular access was important for maintaining a stable TMP and avoiding its related development of hemolysis. Besides, increased TMP and Pa correlate with hemolysis and Pv does not, so clotting of the filters might be associated with an increased risk of hemolysis.
The reported incidence of hemolysis during plasmapheresis varies widely depending on the definition of hemolysis and plasmapheresis methods. 5 In our study, the overall frequency of hemolysis was 35.4%, slightly higher than that of other reported studies. 4, 5 This might be the result of special attention to hemolysis formation in our prospective registry study. The major drawback of this study is that the determination of hemolysis was made by visual inspection of the discoloration in the plasma separator. It was a subjective judgment without quantitative measurement. To avoid interpersonal variability, all recognition of hemolysis was done by the same person. We registered only the presence or absence of hemolysis and did not grade the degree of hemolysis to simplify the discrimination criteria and to reduce intrapersonal variability. Further study with objective tests for hemolysis is needed. Fortunately, hemolysis during DFP treatment was not associated with clinical consequences. 3 Peripheral venous access and a high TMP at M30 were associated with a high risk of hemolysis. Using vascular access through large veins and maintaining a stable TMP during the procedure may help avoid hemolysis during DFP. ❚Figure 3❚ Venous pressure (mean and SD) monitored at 30-minute intervals during the double-filtration plasmapheresis for the hemolysis and no hemolysis groups. P ≤.05 was considered statistically significant.
